These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10805828)

  • 1. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.
    Kovacs JA; Masur H
    N Engl J Med; 2000 May; 342(19):1416-29. PubMed ID: 10805828
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
    Bender MA; Sax PE
    N Engl J Med; 2001 May; 344(21):1639; author reply 1640-1. PubMed ID: 11374364
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy.
    Powderly WG
    Clin Infect Dis; 2000 Aug; 31(2):597-601. PubMed ID: 10987727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002.
    Brooks JT; Song R; Hanson DL; Wolfe M; Swerdlow DL;
    Clin Infect Dis; 2005 Aug; 41(4):549-53. PubMed ID: 16028167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
    Le Moal G; Breux JP; Roblot F
    N Engl J Med; 2001 May; 344(21):1639-41. PubMed ID: 11374363
    [No Abstract]   [Full Text] [Related]  

  • 8. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases.
    Dworkin MS; Williamson J; Jones JL; Kaplan JE;
    Clin Infect Dis; 2001 Aug; 33(3):393-8. PubMed ID: 11438910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV: opportunistic infections.
    Ioannidis J; Wilkinson D
    Clin Evid; 2003 Jun; (9):795-816. PubMed ID: 15366175
    [No Abstract]   [Full Text] [Related]  

  • 10. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
    Jacobson MA; French M
    AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevention and treatment of opportunistic infections in HIV-infected adults.
    HIV Clinician Society of Southern Africa
    S Afr Med J; 2002 Jun; 92(6):426-8. PubMed ID: 12146122
    [No Abstract]   [Full Text] [Related]  

  • 13. Daily trimethoprim-sulfamethoxazole prophylaxis rapidly induces corresponding resistance among intestinal Escherichia coli of HIV-infected adults in Kenya.
    Chiller TM; Polyak CS; Brooks JT; Williamson J; Ochieng B; Shi YP; Ouma P; Greene C; Hamel M; Vulule J; Bopp C; Slutsker L; Mintz E
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):165-9. PubMed ID: 19357424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NONAC update. CMV is still a threat in HIV; treatment guidelines change. New Orleans Nurses In AIDS Care.
    Jarrott CR
    Fac Notes (New Orleans La); 1999; 11(2):5. PubMed ID: 11816501
    [No Abstract]   [Full Text] [Related]  

  • 15. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi.
    Mwaungulu FB; Floyd S; Crampin AC; Kasimba S; Malema S; Kanyongoloka H; Harries AD; Glynn JR; Fine PE
    Bull World Health Organ; 2004 May; 82(5):354-63. PubMed ID: 15298226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotrimoxazole prophylaxis in HIV-infected individuals after completing anti-tuberculosis treatment in Thyolo, Malawi.
    Zachariah R; Spielmann MP; Harries AD; Gomani P; Bakali E
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1046-50. PubMed ID: 12546111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
    Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
    N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection.
    Gill CJ; Sabin LL; Tham J; Hamer DH
    Bull World Health Organ; 2004 Apr; 82(4):290-7. PubMed ID: 15259258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.